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Abstract: The PARP inhibitor olaparib has been approved in the maintenance setting of
platinum-sensitive epithelial ovarian cancer patients with germline or somatic BRCA1/2 mutation.
Therefore, the availability of a tumor BRCA test has become a clinical need. We report the results
of the clinical implementation of a tumor BRCA test within the frame of an institutional workflow
for the management of patients with nonmucinous and nonborderline epithelial ovarian cancer. In
total, 223 patients with epithelial ovarian cancer were prospectively analyzed. BRCA1/2 status was
evaluated on formalin-fixed, paraffin-embedded tumor specimens using next-generation sequencing
technology. The tumor BRCA test had a success rate of 99.1% (221 of 223 successfully analyzed
cases) and a median turnaround time of 17 calendar days. Among the 221 cases, BRCA1 or BRCA2
pathogenic/likely pathogenic mutations were found in 62 (28.1%) cases and variants of uncertain
significance in 25 (11.3%) cases. The concordance rate between tumor BRCA test results and germline
BRCA1/2 status was 87%, with five cases harboring pathogenic/likely pathogenic somatic-only
mutations. The next-generation, sequencing-based tumor BRCA test showed a high success rate and
a turnaround time compatible with clinical purposes. The tumor BRCA test could be implemented in
a molecular diagnostic setting and it may guide the clinical management of patients with epithelial
ovarian cancer.
Keywords: BRCA1/2; ovarian cancer; next-generation sequencing
1. Introduction
Epithelial ovarian cancer (EOC) is the seventh most common cancer among women worldwide [1],
frequently diagnosed in an advanced stage and with an aggressive clinical course [2]. Despite
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surgical resection and standard chemotherapy, the frequency of disease relapse at 5 years may reach
40–75% [3]. The introduction of poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitors
(PARPi) has marked a crucial step forward in the treatment of these patients. Up until now, three
PARPi—olaparib, niraparib, rucaparib—have received the Food and Drug Administrations (FDA)
and European Medicines Agency (EMA) approvals in different clinical settings [4–6]. Olaparib has
been approved in Europe for the maintenance of platinum-sensitive recurrent EOCs patients with a
somatic or germline BRCA1/2 mutation [4]. Moreover, based on the recent striking results of SOLO 1
trial, olaparib will be used as maintenance therapy even for women with newly diagnosed advanced
EOC harboring BRCA1/2 mutations [7]. Therefore, the evaluation of BRCA1 and BRCA2 status is
nowadays mandatory for all patients with advanced nonmucinous EOC to guide the therapy decision.
In this setting, the analysis of BRCA1/2 should meet precise requirements [8,9]. First, the test should be
performed on tumor specimens, enabling to capture both somatic and germline alterations; second,
the test should be suitable for formalin-fixed, paraffin-embedded (FFPE) specimens, available in
all the pathology laboratories; third, the test turnaround time should be consistent with treatment
decision purposes; finally, the test should be included in a comprehensive and multidisciplinary clinical
management of women with EOC.
In the last years, different studies have reported on the implementation and validation of
next-generation sequencing (NGS) platforms to assess the BRCA1/2 status in FFPE specimens [10–12].
Although these NGS panels allowed a shorter test turnaround time (TAT) as compared with standard
Sanger sequencing, the use of these assays in a clinical diagnostic scenario may be challenging [8,9].
In this study, we prospectively analyzed the tumor BRCA1/2 status in FFPE samples from
223 patients with EOC, aiming (i) to ascertain the feasibility of the tumor NGS-based BRCA test in
the clinical setting, and (ii) to evaluate the prevalence of tumor BRCA1 and BRCA2 mutations in a
single-institution cohort of women with epithelial ovarian cancers.
2. Results
2.1. Tumor BRCA Test Performance
All the FFPE tumor samples were considered adequate for the analysis according to the tumor
cell content (more than 10%) and the DNA yield (more than 10 ng). In two cases (0.9%), the NGS
analysis failed due to low NGS run quality parameters and FFPE artifacts. Overall, the median TAT
was 17 calendar days (range 4–50 calendar days) from test request to final molecular report. During the
timeframe of the analysis (25 months), the number of test demands had increased, in association with a
decrease in TAT. In the first trimester, 12 requests had been handled with a median TAT of 33 calendar
days, in the last trimester, 46 requests had been processed with a median TAT of 14 calendar days.
2.2. Tumor BRCA1 and BRCA2 Alterations Distribution
Among the 221 cases successfully analyzed, 62 (28.1%) cases harbored tumor BRCA1 or BRCA2
pathogenic/likely pathogenic mutations. Twenty-five (11.3%) cases harbored a variant of uncertain
significance (VUS), including three cases with BRCA2 VUS and a concurrent BRCA1 pathogenic
mutation. No other co-occurrence of pathogenic or likely pathogenic mutations was observed. Overall,
87 variants were identified (BRCA1 n = 63, 72.4%; BRCA2 n = 24, 27.6%), with a median coverage of
1987 reads and a median variant allele frequency of 70%. In detail, 47 pathogenic/likely pathogenic
mutations and 16 VUS were identified in BRCA1; 15 pathogenic/likely pathogenic mutations and nine
VUS occurred in BRCA2 (Figure 1). The mutations distribution spanned the whole coding sequence of
BRCA1 and BRCA2 gene, without hotspot regions (Figure 2). Eleven and five alterations affecting the
intronic regions were identified in BRCA1 and BRCA2, respectively.
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Figure 1. Tumor BRCA1 (A) and BRCA2 (B) status in the study cohort according to variant classification.
Pie charts representing the distribution (number of cases; percentage) of BRCA1 (A) and BRCA2 (B)
variants among the 221 successfully analyzed. Variant classification is color-coded according to the
legend on the right.
Figure 2. Lollipop plots of mutation distribution on BRCA1 (A) and BRCA2 (B) protein and
domains. The diagrams linearly represent BRCA1/2 protein domains (x-axis). BRCA1 domains:
green, C3HC4-type RING finger; red, serine-rich domain associated with BRCT; blue, ethylene
insensitive 3; yellow, BRCA1 C terminus domain. BRCA2 domains: green, BRCA2 repeats; red, BRCA2
helical; blue, BRCA2 oligonucleotide/oligosaccharide-binding domain 1; yellow, tower; purple, BRCA2
oligonucleotide/oligosaccharide-binding domain 3. Each mutation is represented by single lollipop; the
stick lengths indicate mutation frequency (y-axis), and dots are color-coded according to alteration type:
green, missense mutations; black, truncating mutations (frameshift or nonsense mutations); brown
dots, in-frame mutations. Intronic variants are not reported. Graphs created using Mutation Mapper
tool, cBioportal (http://www.cbioportal.org/mutation_mapper) and manually curated. BRCA1: RefSeq:
NM_007294, Ensembl: ENST00000357654, CCDS: CCDS11453, UniProt: BRCA1_HUMAN. BRCA2:
RefSeq: NM_000059, Ensembl: ENST00000380152, CCDS: CCDS9344, UniProt: BRCA2_HUMAN.
2.3. Tumor BRCA1/2 Status According to Clinicopathological Characteristics
The BRCA1 and BRCA2 mutations prevalence according to clinicopathological parameters was
reported in Table 1. The majority of BRCA1/2 alterations were identified in primary tumors, whereas
only two clinically significant mutations were identified in the sample from the recurrence site. In
the high-grade ovarian serous carcinoma subgroup, 31.4% of cases harbored a clinically significant
mutation (n = 61 cases, 47 BRCA1 and n = 14 BRCA2), whereas only one likely pathogenic BRCA2
alteration was detected in non-high-grade serous carcinoma. Actually, the histotype was the only
clinicopathological parameter showing statistically significant association with the presence of BRCA1/2
mutation (p-value = 0.005) (Table 2). However, a higher frequency of BRCA1/2 mutations was identified
among patients with the tumor BRCA test requested at least 6 months after diagnosis without
disease-relapse (34.3%) as compared with patients with the test performed at diagnosis or disease
relapse (29.3% and 16.2%, respectively). Eleven women with a positive family history previously
underwent surgery for breast cancers, and in five cases BRCA1 (n = 4) or BRCA2 (n = 1), pathogenic
alterations were detected in the ovary tumor samples.
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Table 1. Tumor BRCA1 and BRCA2 alterations distribution according to the clinicopathological parameters of the 221 cases successfully analyzed.
Clinicopathological Features BRCA1 BRCA2
Pathogenic/Likely
Pathogenic Mutations VUS WT
Pathogenic/Likely
Pathogenic Mutations VUS WT
Tumor Site
Primary tumors (n = 200) 46 (23.0%) 13 (6.5%) 141 (70.5%) 14 (7.0%) 7 (3.5%) 179 (89.5%)
Metastases/Recurrences
(n = 21) 1 (4.8%) 3 (14.3%) 17 (81.0%) 1 (4.8%) 2 (9.5%) 18 (85.7%)
Histologycal Subtype
High-grade serous carcinoma
(n = 194) 47 (24.2%) 16 (8.2%) 131 (67.5%) 14 (7.2%) 7 (3.6%) 173 (89.2%)
Non-serous carcinoma/subtype
not defined (n = 27) 0 0 27 (100%) 1 (3.7%) 2 (7.4%) 24 (88.9%)
Pathological Staging
T1 (n = 15) 2 (13.3%) 0 13 (86.7%) 2 (13.3%) 2 (13.3%) 11 (73.3%)
T2 (n = 29) 6 (20.7%) 1 (3.4%) 22 (75.9%) 3 (10.3%) 0 26 (89.7%)
T3 (n = 116) 25 (21.6%) 8 (6.9%) 83 (71.6%) 4 (3.4%) 3 (2.6%) 109 (94.0%)
NA (n = 61) 14 (23.0%) 7 (11.5%) 40 (65.6%) 6 (9.8%) 4 (6.6%) 51 (83.6%)
N0 (n = 39) 5 (12.8%) 0 34 (87.2%) 3 (7.7%) 4 (10.3%) 32 (82.1%)
N1 (n = 65) 18 (2.7%) 6 (9.2%) 41 (63.1%) 2 (3.1%) 1 (1.5%) 62 (95.4%)
NX (n = 56) 10 (17.9%) 3 (5.4%) 43 (76.8%) 4 (7.1%) 0 52 (92.9%)
NA (n = 61) 14 (23.0%) 7 (11.5%) 40 (65.6%) 6 (9.8%) 4 (6.6%) 51 (83.6%)
Family History
Positive (n = 93) 24 (25.8%) 8 (8.6%) 61 (65.6%) 7 (7.5%) 6 (6.5%) 80 (86.0%)
Negative (n = 101) 16 (15.8%) 7 (6.9%) 78 (77.2%) 7 (6.9%) 2 (2.0%) 92 (91.1%)
NA (n = 27) 7 (25.9%) 1 (3.7%) 19 (70.4%) 1 (3.7%) 1 (3.7%) 25 (92.6%)
Time of Test Request
At pathological diagnosis
(n = 123) 28 (22.8%) 8 (6.5%) 87 (70.7%) 8 (6.5%) 5 (4.1%) 110 (89.4%)
At least 6 months after
pathological diagnosis without
relapse (n = 35)
9 (25.7%) 2 (5.7%) 24 (68.6%) 3 (8.6%) 3 (8.6%) 29 (82.9%)
At relapse (n = 37) 4 (10.8%) 5 (13.5%) 28 (75.7%) 2 (5.4%) 1 (2.7%) 34 (91.9%)
NA (n = 26) 6 (23.1%) 1 (3.8%) 19 (73.1%) 2 (7.7%) 0 24 (92.3%)
The bold terms referred to the clinicopathological feature investigated.
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Table 2. Correlation between BRCA status and clinicopathological features.
Clinicopathological Features BRCA MUTATED (Phatogenic/LikelyPathogenic Mutations) BRCA WT * p Value **
Tumor Site
Primary tumors (n = 200) 62 (31.0%) 138 (69.0%)
0.07Metastases/Recurrences (n = 21) 2 (9.5%) 19 (90.5%)
Histologycal Subtype
High-grade serous carcinoma (n = 194) 61 (31.4%) 133 (68.6%)
0.005Non-serous carcinoma/subtype not
defined (n = 27) 1 (3.7%) 26 (96.3%)
Pathological Staging
T1 (n = 15) 4 (26.7%) 11 (73.3%)
0.716
T2 (n = 29) 9 (31.0%) 20 (69.0%)
T3 (n = 116) 29 (25.0%) 87 (75.0%)
NA (n = 61) 20 (32.8%) 41 (67.2%)
N0 (n = 39) 8 (20.5%) 31 (79.5%)
0.518
N1 (n = 65) 20 (30.8%) 45 (69.2%)
NX (n = 56) 14 (25.0%) 42 (75.0%)
NA (n = 61) 20 (32.8%) 41 (67.2%)
Family History
Positive (n = 93) 31 (33.3%) 62 (66.7%)
0.258Negative (n = 101) 23 (22.8%) 78 (77.2%)
NA (n = 27) 8 (29.6%) 19 (70.4%)
Time of Test Request
At pathological diagnosis (n = 123) 36 (29.3%) 87 (70.7%)
0.33
At least 6 months after pathological
diagnosis without relapse (n = 35) 12 (34.3%) 23 (65.7%)
At relapse (n = 37) 6 (16.2%) 31 (83.8%)
NA (n = 26) 8 (30.8%) 18 (69.2%)
* Wild Type (WT) or variants of uncertain significance (VUS) variants. ** p-value < 0.05, statistically significant Chi-Squared Test. The bold terms referred to the clinicopathological
feature investigated.
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2.4. Tumor and Germline BRCA Tests Concordance
Germline BRCA1/2 status was available for 62 patients, including 28 cases with tumor BRCA
status positive (23 pathogenic/likely pathogenic alterations and five VUS). The tumor and germline
BRCA test results are reported in Table 3. Overall, the concordance between tumor and germline BRCA
tests was 87.1% (54 of 62), and the negative predictive value of the tumor test was 100%, as all the
negative tumor cases had a negative germline test result. All the discordant cases were re-tested in
an independent analysis: the specimens were re-evaluated and if available, a different sample was
used for the re-test. In all the cases, the tumor BRCA results were confirmed. Five pathogenic/likely
pathogenic alterations (BRCA1 n = 4 and BRCA2 n = 1) and three VUS in BRCA1 were detected in the
tumor specimens only and were considered somatic mutations.
Table 3. Correlations between tumor and germline BRCA1/2 status (n = 62).
Tumor BRCA Test
Germline BRCA Test
Positive Negative
Pathogenic/Likely Pathogenic VUS
Positive
Pathogenic/Likely Pathogenic 18 (78.3%) / 5 (21.7%)
VUS / 2 (40%) 3 (60%)
Negative / / 34 (100%)
2.5. Tumor BRCA Test Workflow in Clinical Diagnostic Setting
In the present study, we proposed a workflow for the analysis of tumor BRCA1/2 status in
all patients with a diagnosis of nonmucinous and nonborderline EOC, according to the recently
updated AIOM (Associazione Italiana di Oncologia Medica)/SIGU (Società Italiana di Genetica Umana)
/SIBIOC (Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica )/SIAPEC-IAP (Patologica e
Citologia Diagnostica–italian division of International Academy of Pathology) guidelines [13] (Figure 3).
Once the pathological report confirms the diagnosis, the gynecologic oncologist requests the tumor
BRCA test upon discussion with the patients and written information on the potential test results
and implications. The specific informed consent is collected by the clinician and forwarded with the
BRCA test request to the Molecular Diagnostic Unit, where the tumor BRCA test is performed. The
result is validated by the molecular biologist and pathologist in a timeframe expected of 4 weeks
or less. The patient receives and discusses the test result with the gynecologic oncologist. Patients
harboring pathogenic/likely pathogenic tumor BRCA1/2 mutations may be eligible for PARPi therapy,
according to clinical characteristics, and directed to genetic counseling, during which a peripheral
blood sample will be tested to evaluate the germline nature of the alteration identified. In the presence
of a germline variant, prevention measures and the extension of the genetic counseling to the family
members is proposed, according to the institutional procedures. Genetic counseling is advised even
for patients harboring variants of unknown significance in the tumor or with a negative tumor test
result if they have a suggestive clinical phenotype such as a BRCAness clinical phenotype [14] or
their family history is suspicious for hereditary breast and ovarian cancer (HBOC) syndrome. For
these patients, the geneticist evaluates the appropriateness of germline BRCA testing as sequencing of
BRCA1/BRCA2, including the evaluation of large rearrangements or the complementary test seeking
for large rearrangements only.
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Figure 3. Tumor BRCA test workflow. OC: ovarian cancer; PARPi: poly (adenosine diphosphate
(ADP)-ribose) polymerase inhibitors; HBOC: hereditary breast and ovarian cancer.
3. Discussion
To date in Italy, the PARPi olaparib is approved by Agenzia Italiana del Farmaco (AIFA) as
maintenance treatment after a complete or partial response to platinum-based chemotherapy for
patients with recurrent high-grade serous ovarian carcinoma, carcinoma of the fallopian tube, or
primary peritoneal carcinoma, with germline or somatic BRCA1/2 mutation [15]. In addition, the
results of SOLO1 trial in women with newly diagnosed advanced EOC and a BRCA1/2 mutation may
lead to BRCA testing at the time of diagnosis [7]. Hence, the introduction of a diagnostic test able to
identify both germline and somatic BRCA1/2 alterations in tumor specimens has become necessary to
guide treatment choice, even right after the surgery. In this study, we showed the clinical feasibility
of an NGS-based tumor BRCA test and we proposed a BRCA test workflow to improve the clinical
management of women with EOC.
There are critical pre-analytical and analytical issues in the clinical implementation of an NGS-based
BRCA tumor test that are related to (i) the nature of FFPE archival specimens and (ii) the interpretation of
NGS results, including mutation identification and classification [8,9,16]. Previous studies have shown
that next-generation sequencing analyses represent robust and efficient methods for the detection of
BRCA1/2 alterations from FFPE tumor tissue, including ovarian cancer specimen [10–12]. In particular,
two studies validated the use of the NGS panel “Oncomine BRCA Research Assay” for tumor BRCA
testing, performed on FFPE samples from ovarian cancers [12,17]. Here, we demonstrated the feasibility
of the implementation of the NGS-based BRCA tumor tests in a clinical molecular diagnostic setting.
All the FFPE samples met the criteria for NGS analysis, with a BRCA tumor test success rate of 99.1%.
The technology was robust and fully automatized. Given that at least eight samples have to be analyzed
at the same time, with increasing requests of the tumor BRCA test, the TAT from request to results
has been reduced to a median of 17 calendar days. This timeframe was suitable for clinical purposes,
considering both relapse treatment and maintenance therapy in newly diagnosed cancers.
In our study, 28.1% and 11.3% of cases harbored BRCA1/2 pathogenic/likely pathogenic alterations
and VUS, respectively. The mutations distribution in BRCA1 and BRCA2 genes was similar to the data
obtained from larger cohorts [18,19]. No hotspot mutations have been identified, as expected in a
study population originating from all over Italy. We confirmed the association between the BRCA1/2
positive status and high-grade serous carcinoma histological subtype. The frequency of BRCA1/2
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mutations was higher in patients with the tumor test requested at least 6 months after diagnosis
without disease-relapse. Although not statistically significant, this difference may be related to the
favorable prognosis and platinum-sensitivity of tumor with BRCA1/2 mutations [18]. No other clinical
correlation could be evaluated due to the small number of the cases with BRCA1/2 mutation and an
appropriate follow-up.
Compared with germline BRCA1/2 variant testing, the analysis on tumor tissue allow to identify
also somatic alterations. These mutations account for a not insignificant proportion of BRCA1/2 mutated
EOC (3.5–39%), depending on patient selection and histological subtype [18–22]. In the study cohort,
considering the subgroup of patients with an available germline test, we detected a quota of potential
somatic alterations occurring during the tumor development. In detail, 5/23 (21.7%) pathogenic/likely
pathogenic mutations were identified in tumor only. These alterations would not be pinpointed if only
a germline blood-based BRCA test was performed. Moreover, as recently reported by Janice Kwon,
tumor BRCA testing may represent a cost-effective method of triaging women with EOC for genetic
counseling and a confirmatory germline test to identify BRCA1/2 mutations carriers [23].
We proposed a BRCA test workflow for women with EOC that involved pathologists, biologists,
oncologists, surgeons, and geneticists. The aim was first to offer to the patients personalized therapies
both in relapse setting and in first-line maintenance treatment. Secondarily, a primary tumor BRCA
screening would hasten the germline test and so accelerate the genetic counseling process, for specific
cases. Indeed, for patients with BRCA-positive tumor, the germline tests could be at first instance
an assessment in the peripheral blood of the alterations identified in the tumor. Thus, the germline
or somatic nature of the alteration would be ascertained with different burdens, in terms of genetic
counseling. In this workflow, every patient with a diagnosis of nonmucinous and nonborderline EOC
would be tested. This may allow the identification of patients with a BRCA1/2 germline variant even
in the absence of a family history suspicious for HBOC, that otherwise would never be included in
germline BRCA screening. In the systemic review, Arts-de Jong et al. reported a 6.2% mean probability
of finding a germline BRCA1/2 mutation in a patient with ovarian cancer and without a positive family
history for breast and/or ovarian cancer [24]. In the present study, 23 patients with a negative family
history had a BRCA tumor test positive for pathogenic/likely pathogenic alteration. Among these, four
were confirmed as germline variant by a peripheral blood sample test.
The workflow we described could be a “place to start” for clinical management of women with
EOC. Nevertheless, even if the negative predictive value of the tumor BRCA test for identifying
germline variants was 100%, it is undisputed that the clinicians should individually evaluate each
patient. First, the potential limitations of the tumor test should be considered, including the issue of
accurate identification of large rearrangements as well as the tumor heterogeneity associated with the
neoplastic growth [25,26]. Indeed, in our series, one case showed a BRCA1/2 negative status in the
primary tumor and a subsequent BRCA1/2 positive relapse. Second, different studies reported on the
phenomenon of “revertant phenotype”. Although it was not observed in our series, this phenomenon
cannot be excluded a priori [27–29]. Third, we could analyze the concordance between tumor and
germline BRCA tests only in a small subgroup of patients (n = 62/221). For these reasons, we cautiously
suggest performing genetic counseling even when the tumor test is negative but the family history is
suggestive for BRCAness phenotype or the patients had a personal and/or family history suggestive
for HBOC syndrome.
The management of uncertain results of tumor tests remains controversial. Specific guidelines are
needed for the correct handling of these results by both the gynecologic oncologist for therapeutic
purposes and the clinical geneticist for genetic risk assessment. In our view, patients should be
informed about the need for updates regarding the possibility of reclassification of variants of unknown
significance over time.
This study has potential limitations. First, the NGS BRCA panel is currently unsuitable for a
reliable measurement of copy number variants in FFPE specimens (large rearrangements accounting
for less than 10% of BRCA1/2 alterations). At the present time, this pitfall is linked to the PCR
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enrichment methods and bioinformatics algorithms that may overcome this limit are expected. Second,
a higher rate of base call error, especially in the homopolymeric region has been reported with
the amplicon-based and semiconductor NGS technology as compared with other platforms [30–32].
However, in their validation cohort of 43 samples previously analyzed with Illumina platform and/or
by Sanger sequencing, Shin et al. did not identify any false-positive variant calls in the homopolymer
region, considering an allele frequency of ≥20% [17]. The authors concluded that the new Ion Torrent
sequencer with an optimize bioinformatics pipeline may represent an accurate platform for the analysis
of BRCA1/2 genes [17]. Furthermore, to improve the quality of variant call and reduce the error rate,
we performed every sequencing run in duplicate on different chips. Third, given the short follow-up
time and the small number of patients with BRCA1/2 mutations, we were not able to evaluate any
correlation between BRCA1/2 status and clinical outcomes. Further studies with larger cohorts and
adequate follow-up are required to assess the clinical impact of our BRCA workflow. Finally, we have
not investigate the presence of alterations in other genes of the homologous recombination system.
Although this evaluation may have an important clinical impact, we focused on BRCA1/BRCA2 analysis
according to the current standard of care requested for predictive purpose.
4. Materials and Methods
4.1. Study Population
The study population included 223 patients with EOC referred to the Molecular Diagnostics Unit
of the European Institute of Oncology from October 2016 to October 2018 for tumor BRCA1/2 analysis.
The tumor BRCA test was required by gynecologic oncologists after the diagnosis of nonmucinous and
nonborderline EOC, according to the test guidelines [13]. Each patient gave written informed consent
to the tumor BRCA test, form institutional approved and encoded as GNM.MO.5936.B, revised version
23.10.2017.
The clinicopathological characteristics of the study cohort are summarized in Table 4. The clinical
data were collected from medical records. The histological subtype and TNM staging were determined
by gynecologic pathologists according to the current World Health Organization (WHO) classification
of tumors of the female reproductive organs and the 8th Edition American Joint Committee on Cancer
(AJCC) Staging Manual [33,34]. The family history was considered positive when at least one first
degree relative had a BRCA1- or BRCA2-related cancer diagnosis. The test request was submitted
immediately after the histopathological diagnosis for 123 patients, after 6 months or more from
diagnosis for 35 patients without disease relapse, and at the relapse for 37 patients. For 28 patients,
these data were not available. For a subgroup of patients (n = 62), germline BRCA1/2 status was also
available, as previously assessed with peripheral blood testing.
Table 4. Clinicopathological characteristics of the study population.
Clinicopathological Features n (%)
Time of Test Request
At pathological diagnosis 123 (55.2%)
At least 6 months after pathological diagnosis without relapse 35 (15.7%)
At relapse 37 (16.6%)
NA 28 (12.6%)
Histological Subtype
High-grade serous carcinoma 195 (87.4%)
Endometroid carcinoma 16 (7.2%)
Clear cell carcinoma 9 (4%)
Carcinoma—subtype not defined 3 (1.3%)
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Table 4. Cont.
Clinicopathological Features n (%)
TN Pathological Staging
T1 15 (6.7%)
T2 29 (13%)
T3 116 (52%)
NA 63 (28.3%)
N0 39 (17.5%)
N1 65 (29.1%)
NX 56 (25.1%)
NA 63 (28.3%)
Specimen Analyzed
Primary Tumor 201 (90.1%)
Ovary localization 169 (75.8%)
Extra-ovary localization 32 (14.3%)
Pelvic localization 14 (43.8%)
Extra-Pelvic localization 12 (37.5%)
NA 6 (18.7%)
Metastasis/recurrence 22 (9.9%)
Lymph nodal metastasis 3 (13.6%)
Extra lymph nodal metastasis 19 (86.4%)
Neoadjuvant Treatment
Yes 46 (20.6%)
No 114 (51.1%)
NA 63 (28.3%)
Surgery
R0 - no residual disease 135 (60.5%)
R+ < 1 cm 42 (18.8%)
R+ > 1 cm 19 (8.5%)
NA 27 (12.1%)
Family History
Positive 93 (41.7%)
Negative 101 (45.3%)
NA 29 (13%)
The bold terms referred to the clinicopathological features investigated.
4.2. Next-Generation Sequencing Analysis of BRCA Status in Tumor Samples
DNA was extracted from representative formalin-fixed paraffin-embedded (FFPE) tumor tissues
block as previously reported [35]. One hundred and ninety-two (86.1%) cases had FFPE tissue blocks
internally stored, whereas for 31 (13.9%) cases, FFPE material was obtained from external institutions.
In 134 cases (60.1%), manual macrodissection with a sterile scalpel was performed before nucleic acid
isolation. The median tumor cell content was 60% (range 10–90%). BRCA1/2 status was evaluated
using the next-generation sequencing (NGS) panel “Oncomine BRCA Research Assay” (ThermoFisher,
Waltham, MA, USA), following the manufacturer’s instructions. Briefly, 10 ng of genomic DNA was
used for the library preparation, and the subsequent chip loading performed automatically on the
Ion Chef System (ThermoFisher). The sequencing run was done in duplicate using Ion S5 System
(ThermoFisher). Data were analyzed using the Ion Reporter Analysis Software. Only mutations
with an allele frequency ≥5% and with adequate quality metrics were reported [36]. Each clinically
relevant alteration was visually inspected using the Integrative Genomics Viewer (IGV) software
(Broad Institute and the Regents of the University of California, Cambridge, MA, USA). No specific
algorithm for the detection of large insertion/deletion was available for FFPE tissue analysis, therefore,
no copy number variant (CNV) was reported. The mutations were classified in a five-class system
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according to the IARC (International Agency for Research on Cancer) clinical classification and
depending on the ENIGMA consortium revision [37]. The BRCA Exchange database was consulted
for variant classification [38]. If the variant clinical significance was reported as “not yet reviewed”
by ENIGMA consortium, other public databases were questioned, such as ClinVar [39] or Leiden
Open source Variation Database (LOVD) [40]. The analytical workflow of this tumor BRCA test was
previously validated on retrospective cases with known BRCA1/2 status under an inter-laboratory
validation program.
4.3. Statistical Analysis
Statistical analysis was carried out using SPSS Statistic 25 software (IBM, New York, NY, USA).
Chi-Square test with Yates correction was used for data comparison of categorical variables. p-values <
0.05 were considered statistically significant.
5. Conclusions
In conclusion, we showed that the NGS-based tumor BRCA test may be used in the molecular
diagnostic setting for all patients with nonmucinous and nonborderline EOC. The test is suitable for
the analysis of FFPE specimens and generated reliable results in a timeframe compatible with clinical
needs. We proposed a “BRCA test workflow” that we followed for an integrated clinical and diagnostic
management of patients with EOC, in which the tumor BRCA test may act as a compelling tool to
drive a personalized treatment of these women.
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